Weekly Update

Weekly Update: December 20 to December 31, 2021. The website analysis and mapping will be updated every two weeks starting December 2021.

New Studies with results available

12 new RCTs with results are available on our website: see here for vaccine et here for treatment

Asadi M, Diabetes Metab Syndr, 2021 Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial.
Bonifacio L, Antimicrob Resist Infect Control, 2021 Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. Standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors)
Bruen C, SSRN, 2021 Auxora Improves Outcomes in Patients With Severe COVID-19 Pneumonia: A Randomized Clinical Trial
Chuah CH, Clin Infect Dis, 2021 Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial.
Finberg RW, Open Forum Infect Dis, 2021 US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19.
Fralick M, medrxiv, 2021 Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial
Gottlieb RL, N Engl J Med, 2021 Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Jayk Bernal A, N Engl J Med, 2021 Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Leucker TM, JACC Basic Transl Sci, 2021 Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.
Sarhan RM, J Infect Public Health, 2021 Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.
Self WH, Lancet Infect Dis, 2021 Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
Zhuravel SV, EClinicalMedicine, 2021 Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial.

0 new or updated vaccine observational studies with results are available on our website: see here

Studies pending data extraction

42 new pharmacological and/or preventive RCTs:

Arruda E A G, medrxiv, 2021 Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections
Asgardoon M, ResearchSquare, 2021 Efficacy of Levamisole with Standard Care Treatment vs Standard Care in Clinical Presentations of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial
Babalola O, ResearchSquare, 2021 A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria
Bar KJ, J Clin Invest, 2021 A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Byakika-Kibwika P, BMC Infect Dis, 2021 Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
Cannellotto M, Emerg Med J, 2021 Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial.
Chew KW, medrxiv, 2021 Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
Davoodi L, Int J Cardiol Heart Vasc, 2021 Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial.
Diaz R, JAMA Netw Open, 2021 Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Faramarzi H, medrxiv, 2021 Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Gaughan E, medrxiv, 2021 GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of the safety, pharmacokinetics, and potential therapeutic value
Haeberle H, medrxiv, 2021 Inhaled Prostacyclin Improves Oxygenation in Patients with COVID-19-induced Acute Respiratory Distress Syndrome
Holm K, BMC Res Notes, 2021 Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden.
Holubar M, medrxiv, 2021 Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
Huang L, medrxiv, 2021 Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial
Isa F, medrxiv, 2021 Repeat Subcutaneous Administration of REGEN-COV(R) in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19
Kazempour M, Iran J Pharm Res, 2021 Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19.
Marcos M, Thromb Haemost, 2021 Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial.
McKinnon JE, Int J Infect Dis, 2021 Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.
Merchante N, Antimicrob Agents Chemother, 2021 Early Use of Sarilumab in Patients Hospitalised with COVID-19 Pneumonia and Features of Systemic Inflammation.
Millat-Martinez P, medrxiv, 2021 Convalescent plasma for outpatients with early COVID-19
Montalvan E, Chest, 2021 High-dose vs low-dose dexamethasone in patients with covid-19 in a tertiary hospital in western honduras
Mordyk A, Infektsionnye Bolezni, 2021 Interferon alpha-2b in comprehensive treatment of patients with covid-19
Morici N, merdrxiv, 2021 Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial
Nair PR, Respir Care, 2021 Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia.
Novartis Pharmaceuticals Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
Ortigoza MB , JAMA Intern Med, 2021 Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial
Ospina-Tascon GA, JAMA, 2021 Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial.
Panda PK, Clin Pharmacol, 2021 Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19.
Pupim L, Ann. Rheum. Dis, 2021 Mavrilimumab improves outcomes in phase 2 trial in non-mechanically-ventilated patients with severe covid-19 pneumonia and systemic hyperinflammation
Ravishankar R, SSRN, 2021 Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Efficacy, Safety and Tolerability of Antiviral Drug Umifenovir vs Standard Care of Therapy in Non-Severe Covid-19 Patients
Reis G, Lancet Glob. Health, 2021 Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial.
Roshon M, Infect Dis Ther, 2021 A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection.
Sabitovi A, Antibiot. Khimioter., 2021 The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19
Seong S, ResearchSquare, 2021 A multicenter, randomized, double-blind, placebo-controlled phase ii trial of intravenous inflammasome inhibitor (NuSepin) for the treatment of COVID-19 patients
Shenoy S , medrxiv, 2021 Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.
Song JY, medrxiv, 2021 Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity
Sullivan D, medrxiv, 2021 Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
Taboada M, Eur Respir J, 2021 Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial.
Tornero C, medrxiv, 2021 Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)
Toroghi N, Pharmacol Rep, 2021 Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial
Zhang Q, Infect Dis Ther, 2021 A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2.

9 new vaccine RCTs:

Halperin SA, Lance, 2021 Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinde
Haranaka M, Nat Commun, 2021 A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.
Hernandez-Bernal F, medrxiv, 2021 Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Li G, SSRN, 2021 Safety and Immunogenicity of the ChadOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 12-17 Years: A Preliminary Report of a Phase 2, Single-Blind, Randomised Controlled Trial (COV006)
Liu J, J Infect Dis, 2021 Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.
Mallory R, medrxiv, 2021 Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Munro A , Lancet, 2021 Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Reindl-Schwaighofer R, JAMA Intern Med, 2021 Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
Stuart A, Lancet, 2021 Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

We have identified additional COVID-19 RCTs assessing:

  1. long COVID
  2. other interventions (dietary supplements or minerals and other technologies (e.g. cytokine adsorption)
  3. other COVID vaccines.

These interventions were not prioritized but they might be included in the future. Details here